Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00690625 · ClinicalTrials.gov registry record · Phase 1
Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00690625 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 40 participants.
The verdict
NCT00690625, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is designed to evaluate the effectiveness of topical application of omega-3 fatty acids (6% by volume) containing cream on persons with a TMD disorder, specifically with a diagnosis of Myofacial Pain. Omega-3 fatty acids have minimal side effects when applied topically. If Omega-3 fatty acids used in this study are shown to reduce myofacial pain then this formulation could potentially be used for treatment of TMD patents with myofacial pain in the future. Omega-3 fatty acids are natural ingredients with almost no side effects. Topical application can lead to fewer side effects than systemic medications. In addition, there is no substantial morbidity \& mortality associated with topical application of Omega-3 fatty acids. It is hypothesized that subjects receiving topical application of omega-3 fatty acids will demonstrate reduced subjective masseter muscle pain in comparison to subjects receiving placebo cream. This is a pilot study to assess the topical application of Omega-3 fatty acids on muscle pain in the muscles of mastication.
Interventions
- DRUG MyoRx Cream (6% Omega 3 Fatty Acid)
- DRUG Placebo cream, no Omega 3 fatty acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00690625
The ClinicalTrials.gov registry entry for NCT00690625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MyoRx Cream (6% Omega 3 Fatty Acid) is the first listed.
NCT00690625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00690625 about?
NCT00690625 is a clinical study titled "Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream". This study is designed to evaluate the effectiveness of topical application of omega-3 fatty acids (6% by volume) containing cream on persons with a TMD disorder, specifically with a diagnosis of Myofacial Pain. Omega-3 fatty acids have minimal side effects when applied topically. If Omega-3 fatty a...
What is the current status of trial NCT00690625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-04. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00690625?
The interventions under investigation include: MyoRx Cream (6% Omega 3 Fatty Acid) (DRUG), Placebo cream, no Omega 3 fatty acid (DRUG).
Who is sponsoring clinical trial NCT00690625?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.